Patents Assigned to Talengen International Limited
  • Patent number: 11938172
    Abstract: The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: March 26, 2024
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Publication number: 20240000903
    Abstract: The present invention relates to a method for promoting the formation of mature BDNF and increasing the level of BDNF. The method comprises administering a therapeutically effective amount of a plasminogen pathway activator to a subject. The present invention also relates to a pharmaceutical composition, a product and a kit which comprises the plasminogen pathway activator and are used for promoting the formation of mature BDNF and increasing the BDNF level.
    Type: Application
    Filed: November 17, 2021
    Publication date: January 4, 2024
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20240000904
    Abstract: The present invention relates to a method for promoting the formation of mature NGF and increasing the expression of NGF. The method comprises administering a therapeutically effective amount of a plasminogen pathway activator to a subject. The present invention further relates to a pharmaceutical composition, a product and a kit comprising the plasminogen pathway activator for promoting the formation of mature NGF and increasing the expression of NGF.
    Type: Application
    Filed: November 17, 2021
    Publication date: January 4, 2024
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230346897
    Abstract: Provided in the present invention is a method for promoting the degradation of a misfolded protein and an aggregate thereof. The method includes administrating a therapeutically effective amount of plasminogen activation pathway components to a subject. Further provided in the present invention are a drug containing the plasminogen activation pathway components, a pharmaceutical composition, a product and a kit, which are used to prevent and treat diseases caused by the misfolded protein and/or the aggregate thereof.
    Type: Application
    Filed: March 24, 2021
    Publication date: November 2, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230302102
    Abstract: The present invention provides a method for treating a tumor in a subject, maintaining or improving body organ function under tumor conditions, and prolonging the survival period of the subject, comprising administering to the subject a prophylactically and/or therapeutically effective amount of components such as plasminogen of a plasminogen activation pathway. The present invention also provides a medicament comprising plasminogen, a pharmaceutical composition, a formulation and a kit for treating a tumor in a subject.
    Type: Application
    Filed: August 20, 2021
    Publication date: September 28, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230190891
    Abstract: The present application relates to a method for treating spinal muscular atrophy (SMA), comprising: administering a therapeutically effective amount of a plasminogen pathway activator to a subject. The present application also relates to a pharmaceutical composition, product, and kit comprising said plasminogen pathway activator, which are used for treating spinal muscular atrophy.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 22, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230181699
    Abstract: Provided is a method for treating spinal muscular atrophy (SMA), comprising: administrating a therapeutically effective amount of a plasminogen pathway activator to a subject. Further provided are a pharmaceutical composition, product and kit comprising said plasminogen pathway activator, which are used for treating spinal muscular atrophy.
    Type: Application
    Filed: November 17, 2020
    Publication date: June 15, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230173039
    Abstract: The present invention provides a method and drug for preventing and treating Alzheimer disease. The method includes: administering a therapeutically effective amount of a component of a plasminogen activation pathway to a subject. The present invention also provides a drug, pharmaceutical composition, product, and kit containing the component of the plasminogen activation pathway.
    Type: Application
    Filed: March 24, 2021
    Publication date: June 8, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230143354
    Abstract: Provided is a method for preventing and treating Parkinson's disease, including administering to a subject a therapeutically effective amount of a component of a plasminogen activation pathway. The present invention relates to a drug, a pharmaceutical composition, a product and a kit which include the component of the plasminogen activation pathway for treating the described condition.
    Type: Application
    Filed: March 24, 2021
    Publication date: May 11, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230141921
    Abstract: Provided are a method and drug for treating Huntington's disease, which includes: administering a therapeutically effective amount of a component of a plasminogen activation pathway or a related compound thereof to a subject. Also provided are a drug, pharmaceutical composition, product, and kit used for treating Huntington's disease and containing the above component or compound.
    Type: Application
    Filed: March 24, 2021
    Publication date: May 11, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Patent number: 11642397
    Abstract: The present invention relates to a method and a drug for preventing or treating osteoarthritis by plasminogen. Specifically, the present invention involves administering an effective amount of plasminogen to an osteoarthritis subject for treating the osteoarthritis. In addition, the present invention further relates to an osteoarthritis treatment drug comprising plasminogen, a product, and a kit.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: May 9, 2023
    Assignee: TALENGEN INTERNATIONAL LIMITED
    Inventor: Jinan Li
  • Publication number: 20230139956
    Abstract: The present application relates to a method for treating abnormal blood pressure condition, which comprises: administrating an effective amount of a component of plasminogen activation pathway to a subject. The present application also relates to a medicament and a product for treating an abnormal blood pressure condition, and use thereof.
    Type: Application
    Filed: February 26, 2021
    Publication date: May 4, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230081922
    Abstract: Provided is a method for treating viral pneumonia, comprising: administrating a therapeutically effective amount of a component of plasminogen activation pathway to a subject. Also provided are a medicament, a pharmaceutical composition, a product, and a kit which comprise a component of plasminogen activation pathway for treating viral pneumonia.
    Type: Application
    Filed: February 8, 2021
    Publication date: March 16, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230084586
    Abstract: Provided is a method for preventing and treating multiple sclerosis, comprising administering a therapeutically effective amount of a component of plasminogen activation pathway to a subject. Also provided are a medicament, a pharmaceutical composition, a product, and a kit which comprise a component of plasminogen activation pathway for treating said disease.
    Type: Application
    Filed: February 8, 2021
    Publication date: March 16, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Publication number: 20230066726
    Abstract: Provided is a method for treatment of nerve injury and a related disease, comprising: administrating a therapeutically effective amount of a component of plasminogen activation pathway to a subject. Also provided are a medicament, a pharmaceutical composition, a product, and a kit which comprise a component of plasminogen activation pathway for treating the above diseases.
    Type: Application
    Filed: January 18, 2021
    Publication date: March 2, 2023
    Applicant: Talengen International Limited
    Inventor: Jinan LI
  • Patent number: 11547746
    Abstract: The present invention relates to a method for preventing and/or treating coronary atherosclerosis and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject, wherein the subject suffers from, is suspected of suffering from coronary atherosclerosis and its related conditions, or has a risk of suffering from coronary atherosclerosis and its related conditions. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating coronary atherosclerosis and its related conditions in a subject.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 10, 2023
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 11478535
    Abstract: The present invention relates to a method for preventing and/or treating fatty liver and its related conditions in a subject, comprising administering an effective amount of plasminogen to the subject; in another aspect, the present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating fatty liver and its related conditions in the subject.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: October 25, 2022
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 11400142
    Abstract: The present invention relates to the use of plasminogen in the prevention and/or treatment of diabetic neuropathic pain and neurohypersensitivity, and in the repair of nerve tissue injury. Therefore, plasminogen may become a new strategy for preventing and treating diabetic neuropathic pain.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: August 2, 2022
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 11389515
    Abstract: The present invention relates to a method for preventing and/or treating hyperlipemia and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject susceptible to hyperlipemia, suffers from hyperlipemia or other diseases accompanied by hyperlipemia. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating hyperlipemia and its related conditions in a subject.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: July 19, 2022
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 11338022
    Abstract: The present invention relates to the effect of plasminogen in the treatment and/or elimination of angiocardiopathy, especially angiocardiopathy caused by diabetes mellitus, thereby providing a new strategy for treating different kinds of angiocardiopathy, especially angiocardiopathy and its related disorders caused by diabetes mellitus.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 24, 2022
    Assignee: TALENGEN INTERNATIONAL LIMITED
    Inventor: Jinan Li